New pill shows promise for diabetes control in Real-World study

NCT ID NCT04601740

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 145 adults with type 2 diabetes who took once-daily oral semaglutide (Rybelsus) as part of their normal care. Researchers measured changes in blood sugar (HbA1c) and body weight over 8-10 months. The goal was to see how well the medication works in everyday life, not just in strict research settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
oral semaglutide (Rybelsus)
What this could lead to
If successful, this study could confirm that oral semaglutide helps control blood sugar and reduce weight in real-world type 2 diabetes patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also small (145 people) and only in the Netherlands, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Master Centre Netherlands

    Alphen aan den Rijn, 2408 AV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.